Adjuvant cytokine-induced killer cell immunotherapy for hepatocellular carcinoma: a propensity score-matched analysis of real-world data

Autor: Jeong Hoon Lee, Hyo Young Lee, Yun Bin Lee, Eun Ju Cho, Joon Hyeok Lee, S.-W. Kim, Jun Sik Yoon, Jung Hwan Yoon, Su Jong Yu, Young Chang, Yoon Jun Kim, Byeong Geun Song, Dong Hyun Sinn
Rok vydání: 2019
Předmět:
Male
0301 basic medicine
Oncology
Cancer Research
medicine.medical_treatment
Immunotherapy
Adoptive
law.invention
Cytokine-Induced Killer Cells
0302 clinical medicine
Randomized controlled trial
law
Interquartile range
Clinical endpoint
Overall survival
Adjuvant immunotherapy
Cytokine-induced killer cell
Liver Neoplasms
Hazard ratio
Middle Aged
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Combined Modality Therapy
Survival Rate
030220 oncology & carcinogenesis
Hepatocellular carcinoma
Female
Adjuvant
Research Article
medicine.medical_specialty
Carcinoma
Hepatocellular
Transplantation
Autologous
lcsh:RC254-282
Disease-Free Survival
03 medical and health sciences
Internal medicine
Republic of Korea
Genetics
medicine
Humans
Propensity Score
Aged
Retrospective Studies
business.industry
Immunotherapy
Recurrence-free survival
medicine.disease
030104 developmental biology
business
Hepatocelluar carcinoma
Zdroj: BMC Cancer, Vol 19, Iss 1, Pp 1-10 (2019)
BMC Cancer
ISSN: 1471-2407
Popis: Background Several randomized controlled trials have shown that adjuvant immunotherapy with autologous cytokine-induced killer (CIK) cells prolongs recurrence-free survival (RFS) after curative treatment for hepatocellular carcinoma (HCC). We investigated the efficacy of adjuvant immunotherapy with activated CIK cells in real-world clinical practice. Methods A total of 59 patients who had undergone curative surgical resection or radiofrequency ablation for stage I or II HCC, and subsequently received adjuvant CIK cell immunotherapy at two large-volume centers in Korea were retrospectively included. Propensity score matching with a 1:1 ratio was conducted to avoid possible bias, and 59 pairs of matched control subjects were also generated. The primary endpoint was RFS and the secondary endpoints were overall survival and safety. Results The median follow-up duration was 28.0 months (interquartile range, 22.9–42.3 months). In a univariable analysis, the immunotherapy group showed significantly longer RFS than the control group (hazard ratio [HR], 0.42; 95% CI, 0.22–0.80; log-rank P = 0.006). The median RFS in the control group was 29.8 months, and the immunotherapy group did not reach a median RFS. A multivariable Cox proportional hazard analysis showed that immunotherapy was an independent predictor for HCC recurrence (adjusted HR, 0.38; 95% CI, 0.20–0.73; P = 0.004). The overall incidence of adverse events in the immunotherapy group was 16/59 (27.1%) and no patient experienced a grade 3 or 4 adverse event. Conclusions The adjuvant immunotherapy with autologous CIK cells after curative treatment safely prolonged the RFS of HCC patients in a real-world setting. Electronic supplementary material The online version of this article (10.1186/s12885-019-5740-z) contains supplementary material, which is available to authorized users.
Databáze: OpenAIRE
Externí odkaz: